Background: Intrauterine Candida albicans infection causes severe fetal inflammatory responses and fetal injury in an ovine model. We hypothesized that intra-amniotic antifungal therapy with fluconazole would decrease the adverse fetal effects of intra-amniotic C. albicans in sheep. Methods: Sheep received an intra-amniotic injection of 10 7
colony-forming units C. albicans. After 2 d, animals were then randomized to: (i) intra-amniotic and fetal intraperitoneal saline with delivery after 24 h (3 d C. albicans group); (ii) intra-amniotic and fetal intraperitoneal injections of fluconazole with delivery after either 24 h (3 d C. albicans plus 1 d fluconazole group) or 72 h (5 d C. albicans plus 3 d fluconazole group). Controls received intra-amniotic injections of saline followed by intraamniotic and fetal intraperitoneal fluconazole injections. results: Intra-amniotic C. albicans caused severe fetal inflammatory responses characterized by decreases in lymphocytes and platelets, an increase in posterior mediastinal lymph node weight and proinflammatory mRNA responses in the fetal lung, liver, and spleen. Fluconazole treatment temporarily decreased the pulmonary and chorioamnion inflammatory responses. conclusion: The severe fetal inflammatory responses caused by intra-amniotic C. albicans infection were transiently decreased with fluconazole. A timely fetal delivery of antimicrobial agents may prevent fetal injury associated with intrauterine infection. P reventing preterm birth (delivery before 37 wk completed gestation) is a major challenge in perinatal medicine with the potential to prevent ~1 million perinatal deaths each year. Although the causes of preterm birth are multifactorial, intrauterine infection is frequently implicated (1) . Many intrauterine infections associated with preterm labor are indolent, not clinically apparent and polymicrobial in nature (2, 3) . Although the most common microorganisms associated with preterm delivery that are identified by culture and molecular-based analyses are bacteria such as the Fusobacterium, Ureaplasma, Mycoplasma, Streptococcus, Bacteroides, and Prevotella spp., up to 40% of pregnant woman may also have vaginal colonization with the yeast, Candida spp. (2, 4) .
The detection of Candida spp. is twofold higher than for nonpregnant women (5) , and Candida spp. have been isolated from the amniotic fluid of women with spontaneous preterm birth (6) (7) (8) . Although congenital candidiasis is an uncommon clinical finding, recent molecular data suggest that C. albicans may colonize the amniotic cavity more frequently than initially indicated by culture-based analyses (7) . Indwelling contraceptives and cervical cerclage are also associated with funisitis and chorioamnionitis caused by Candida spp. (2, 9) . Intra-amniotic Candida spp. infection can cause fetal death or fetal candidiasis with impaired neurodevelopmental outcomes (10, 11) . Again, although vaginal Candida spp. colonization is not frequently associated with increased risk of preterm delivery or low birth weight (12) , there is some evidence that eradication of Candida spp. in pregnancy may reduce the risk of late miscarriage and preterm birth. A large retrospective cohort study demonstrated that the use of clotrimazole was associated with a significant reduction in preterm births and an increase in mean gestational age at birth (13) . A recent study also reported that nearly 20% of women had asymptomatic vaginal candidiasis and there was a tendency toward reduction in spontaneous preterm birth among women who were treated with clotrimazole (14) .
We previously described models of the fetal inflammatory response syndrome in sheep using the proinflammatory mediators Escherichia coli lipopolysaccharides (15) , interleukin (IL)-1 (16) , and live Ureaplasma parvum (17) . In contrast to the low-grade fetal inflammation caused by these agonists, we recently reported that intra-amniotic C. albicans caused a severe, progressive fetal inflammation within 2 d, with the severity of skin, lung inflammatory, and systemic responses threatening fetal viability (18) .
Recent studies have described cases of intra-amniotic C. albicans infection that were successfully treated with
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Articles intra-amniotic fluconazole (19) . Fluconazole is a trizaole antifungal agent that is commonly used to treat vaginal candidiasis. Although there are some concerns regarding the use of fluconazole in pregnancy, its efficacy against Candida spp., long half-life and gastrointestinal uptake make it a potentially useful agent to treat intrauterine infections caused by C. albicans (20) (21) (22) . Therefore, we hypothesized that timely antifungal treatment with fluconazole would decrease the adverse fetal effects of intra-amniotic C. albicans in a pregnant sheep model.
RESULTS

Outcomes at Delivery and Cells in Cord Blood
The fetal mortality rate was 14% (6/40 animals) ( Table 1) . One saline-treated control fetus died prior to delivery. 25% of the 3 d C. albicans-plus 1 d fluconazole and 37% of the 5 d C. albicans plus 3 d fluconazole-exposed animals died. We did not include a 5 d C. albicans only group as we anticipated 100% mortality based on the significant degree of C. albicans infectionassociated pathology identified in our earlier work with this model system (18) . There were no differences in birth weights between saline-only and fluconazole-only control treatment animals, and these were combined as a single control group. Lymphocyte counts for the 3 d C. albicans group significantly decreased relative to control (P < 0.05). In contrast, there were no significant changes in neutrophil and monocyte counts between groups. Platelets significantly decreased in the 3 d C. albicans group and 3 d C. albicans plus 1 d fluconazole group relative to control (P < 0.05). Thus, intra-amniotic C. albicans infection caused a systemic fetal inflammatory response as indicated by lymphopenia and thrombocytopenia in fetal blood counts.
Detection of C. albicans
All animals in the 3 d C. albicans group had positive cultures for C. albicans in amniotic fluid ( Table 1) . All of C. albicansexposed animals that were treated with fluconazole also had positive cultures for C. albicans in the amniotic fluid. The majority of the C. albicans-exposed fetuses also had positive blood cultures, irrespective of fluconazole treatment 1 or 3 d prior to delivery. qPCR analysis demonstrated significantly increased C. albicans RNA in the fetal lung in all groups relative to control (P < 0.05). The amount of C. albicans RNA trended to be less for the 3 d C. albicans plus 1 d fluconazole group than for 3 d C. albicans group (P = 0.06). No C. albicans RNA was detected in the fetal liver in any of the groups ( Table 1) .
Inflammation in Fetal Lungs
Pulmonary inflammation was evaluated by measuring mRNA expression for proinflammatory cytokines (Figure 1) . mRNA for IL-1β, IL-8, MCP-1, and TNF-α in the fetal lung greatly increased in all C. albicans-exposed groups relative to control. mRNA expression for all cytokines significantly increased in To better demonstrate the cellular inflammatory response and activation in the lung, inflammatory cell counts were performed for cells expressing CD3 (T-cell), PU.1 (a maturation marker for myeloid and lymphoid cells, found in high levels in (Figures 3b-d) . SP-A mRNA levels were significantly increased in the 3 d C. albicans group and 5 d C. albicans plus 3 d fluconazole group relative to control (P < 0.05). SP-B mRNA levels were significantly increased only in the 3 d C. albicans group and SP-D mRNA levels trended to increase in all groups relative to control.
Inflammation in Other Organs
Inflammation of the chorioamnion was assessed by measuring expression of proinflammatory cytokines (Figure 4a-c) . mRNA expression of IL-6 significantly increased in the 5 d C. albicans plus 3 d fluconazole group relative to control (P < 0.05). In the 3 d C. albicans plus 1 d fluconazole group, mRNA expression for IL-1β, IL-6, and MCP-1 significantly decreased relative to the 3 d C. albicans group (P = 0.03, P = 0.001, and P = 0.03, respectively). No changes in IL-1α, IL-8, and TNF-α mRNA expression were detected (data not shown). Histology evaluated with hematoxylin and eosin staining demonstrated minimal inflammatory cells in the chorioamnion (data not shown). The membranes were clear except for large white plaques (Figure 4d) .
We evaluated the weight of the posterior of mediastinal lymph node as this node receives lymphatic flow from the lung and gastrointestinal tract (23) . The posterior of mediastinal lymph node to body weight ratio significantly increased in the 
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Articles tended to increase in the 3 d C. albicans group but decreased in both 3 and 5 d C. albicans and fluconazole-exposed groups relative to control (data not shown). Hepatic inflammation was assessed by measuring mRNA expression for the acute phase response proteins, SAA3 and C-reactive protein (CRP). SAA3 and CRP mRNA expression was significantly increased in all groups relative to control (P < 0.05) (Figure 5b,c) . In the fetal spleen, mRNA for IL-6 significantly increased in the 3 d C. albicans group and 5 d C. albicans plus 3 d fluconazole group relative to control (P < 0.05) (Figure 5d ).
DISCUSSION
Systemic fungal and yeast infections are a significant problem for infants requiring intensive care, and the major yeast pathogen in preterm infants is C. albicans (10, 24) . In healthy pregnant women, Candida spp. are common vaginal organisms that rarely infect the normal fetus. However, Candida spp. can cause ascending infection in association with preterm labor or preterm rupture of membranes (25) . Candida spp. have been cultured from amniotic fluid of women with spontaneous preterm birth (7, 26) . In humans and animal models, there is limited information about the inflammatory responses of the fetus to C. albicans. We previously described the multiorgan fetal inflammatory responses to intra-amniotic C. albicans in an ovine model of pregnancy (19) . In this current study, we replicate this inflammatory response and demonstrate that a single dose of the fungal-static drug fluconazole initially suppresses the fetal infection and associated fetal inflammatory response but is unlikely to be effective in a single-dose regimen for the treatment of intra-amniotic C. albicans infection. The characteristics of the fetal inflammatory response caused by C. albicans colonization of the amniotic cavity should be interpreted within the context of other sheep models of chorioamnionitis and fetal inflammatory response syndrome. An intra-amniotic injection of lipopolysaccharides causes acute chorioamnionitis, striking lung inflammation, lung maturation, and a mild systemic inflammation in multiple organs including the gut, liver, skin, and the immune system (spleen, thymus, lymph node) (15, 27) . In contrast, U. parvum colonizes the amniotic fluid, fetal membranes, and lung but with Articles Maneenil et al.
less systemic inflammation and inconsistent lung maturation (17) . Intra-amniotic C. albicans causes a substantially different inflammatory response, characterized by severe inflammation in the fetal lung, inflammation and edema of the fetal skin (18), and fetal death beyond 3 d of exposure. Interestingly, despite a robust intrauterine response, there were no overt effects on the well-being of the ewe, further underscoring the potential for significant fetal involvement to adopt a subclinical course. There is less histological chorioamnionitis observed with C. albicans, but the multiorgan fetal effects are far more severe. Table 1) . Fluconazole is a fungal-static drug and would not be expected to clear the infection without effective innate immune responses, which may be minimal in these naive Although there have been many previous attempts to reduce the rate of preterm birth with the use of antibiotic therapy, all with varying results (28) , very few studies have demonstrated the effects of intrauterine antifungal therapy in pregnant women with Candida spp. infection. In one report, a pregnant woman with premature rupture of membranes and intra-amniotic infection with C. albicans was treated with transcervical amniofusion of amphotericin B and the infant was delivered without complications (29) . Recently, Bean et al. (19) reported the resolution of two cases of intra-amniotic C. albicans infection with maternal and intra-amniotic fluconazole treatment. Thus, treatment of intra-amniotic C. albicans infection with intrauterine antifungal therapy may be helpful but further studies are needed to evaluate the effectiveness and possible toxicity of the therapeutic agent.
A limitation of this study is the absence of measurements of fluconazole levels within the fetal circulation, making it difficult to determine whether the five fetal deaths that occurred among the 16 animals comprising the fluconazole-treated groups are due, at least in part, to fetotoxic drug effects. The use of a combined intra-amniotic and fetal intraperitoneal dosing strategy was designed to ensure drug delivery to both the fetus and amniotic fluid. A drawback to this approach is that we are unable to determine differences or additive effects in therapeutic efficacy or fetotoxicity conveyed by these two delivery strategies. There are concerns relating to the use of fluconazole in pregnancy; it has been shown to have teratogenic effects in several animal model studies and recent in vivo work in a mouse model suggests that fluconazole perturbs CYP 26, an enzyme involved in retinoic acid homeostasis (30) . Interestingly, fluconazole treatment was well tolerated in the control group, suggesting that if fluconazole does have fetotoxic effects it may be more pronounced in conjunction with a pre-existing pathology or fetal stress, including intrauterine infection. Perhaps reassuringly, a number of retrospective cohort studies have failed to demonstrate an increased risk of congenital malformation in association with fluconazole use in pregnancy (22, 31, 32) . Irrespective, further studies are warranted in order to determine the potential adverse effects deriving from exposing the fetus to high levels of fluconazole. A further limitation of this study was our decision to deliver two of the animals in the 5 d C. albicans plus 3 d fluconazole group 24 h early (equivalent to 4 d C. albicans and 2 d fluconazole exposure) due to concerns over fetal well-being. Although we are able to demonstrate that treatment efficacy was similarly reduced in these animals, data from this group does need to be interpreted with this difference in exposure length in mind.
In the current study, we administered a high dose by intraamniotic and fetal intraperitoneal injections but failed to clear C. albicans from the amniotic fluid within 24 h. The efficacy of drugs may be altered in pregnant women due to physiologic changes and some drugs require higher dosing as a result of changes in fluid volumes. Administration of medication by amniocentesis facilitates the direct treatment of the fetus (19) .
Fluconazole is absorbed orally and thus could achieve continuous but decreasing fetal exposures with fetal swallowing. Our novel data demonstrate that although intra-amniotic fluconazole therapy for intrauterine C. albicans infection initially decreases adverse fetal effects, as indicated by a reduction in the lung and chorioamnion inflammation in a single-dose regimen, it is unlikely to prolong fetal survival beyond 5 d. A better understanding of the host immune response to C. albicans infection and as well as responses to multiple dose antifungal treatment regimens will help in the design of new therapies in perinatal medicine.
METHODS
Animals
All procedures involving animals were conducted at The University of Western Australia (Perth, WA) following review and approval by the animal care and use committees of The University of Western Australia and Cincinnati Children's Hospital (Cincinnati, OH). Datemated Merino ewes with singleton pregnancies were randomized to one of the following exposure groups: (i) Control: intra-amniotic injection of 2 ml saline (n = 11) or intra-amniotic and fetal intraperitoneal injections of fluconazole (Claris Lifesciences Limited, Ahmedabad, India) (n = 5); or (ii) C. albicans at day 3 prior to delivery: intra-amniotic injection of 10 7 colony-forming unit (CFU) C. albicans in 2 ml saline 3 d prior to delivery (n = 8; one animal was found to be uninfected at postmortem and was eliminated from subsequent analyses, yielding a group n of 7); or (iii) C. albicans at day 3 prior 
